On Monday, Novo Nordisk A/S (NYSE:NVO) released the headline results from the SOUL Phase 3 cardiovascular outcomes trial.

Sotagliflozin is used to reduce the risk of cardiovascular death and hospitalization for heart failure in adults.

Cancer, malaria and pneumonia continue to be some of Kenya’s biggest health challenges despite the scale-up of intervention tools, and that is expected to be the case in coming years.

Here's all you need to know about Ozempic that Karan Johar is said to have used for fast weight loss. What are the benefits ...

Researchers describe how -- even more than just the presence of sugar and salt in the diet -- having more ultra-processed foods laden with additives can lead to higher average blood glucose levels ...

People who eat more ultra-processed foods (UPF) are at increased risk of developing type 2 diabetes, but this risk can be lowered by consuming less processed foods instead, finds a new study led by ...

(IN BRIEF) Novo Nordisk’s SOUL trial has shown that oral semaglutide reduces the risk of major adverse cardiovascular events ...

BAGSVAERD, Denmark I1, 2024 I Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, ...

HbA1c testing is crucial for diabetes management as it reflects average blood sugar levels over three months, unlike ...

Early control of HbA1c levels and weight in people with diabetes significantly reduces cardiac disease risk. Delays in ...

Novo Nordisk said on Monday an oral version of its drug semaglutide, helped significantly reduce the risk of cardiovascular ...